Powder: -20°C for 3 years | In solvent: -80°C for 1 year
SB290157 trifluoroacetate 是一种选择性 C3a 受体拮抗剂,IC50值为200 nM。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 223 | 现货 | ||
5 mg | ¥ 497 | 现货 | ||
10 mg | ¥ 797 | 现货 | ||
25 mg | ¥ 1,620 | 现货 | ||
50 mg | ¥ 2,820 | 现货 | ||
100 mg | ¥ 4,180 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 576 | 现货 |
产品描述 | SB290157 trifluoroacetate is a potent and selective antagonist of C3a receptor(IC50 of 200 nM). |
靶点活性 | C3a:200 nM |
体外活性 | SB 290157 is a competitive antagonist of 125I-C3a radioligand binding to rat basophilic leukemia-2H3 cells expressing the human C3aR (RBL-C3aR, IC50 of 200 nM). SB 290157 blocks C3a-induced C3aR internalization in a concentration-dependent manner and C3a-induced Ca2+ mobilization in RBL-C3aR cells and human neutrophils (IC50s of 27.7 and 28 nM, respectively). SB 290157 is selective for the C3aR in that. SB 290157 also inhibits C3a-induced Ca2+ mobilization of RBL-2H3 cells expressing the mouse and guinea pig C3aRs. It potently inhibits C3a-mediated ATP release from guinea pig platelets and inhibits C3a-induced potentiation of the contractile response to field stimulation of perfused rat caudal artery[1]. |
体内活性 | Neutrophil recruitment in a guinea pig LPS-induced airway neutrophilia model inhibited by SB 290157 ,SB 290157 decreases paw edema in a rat adjuvant-induced arthritis model[1]. The antagonist is able to reduce joint swelling only at 3 h, and about 50% inhibition of joint swelling is observed with the concentration of 30 mg/kg. The C3 level is significantly decreased at 3 h compared with naive mice showing complement consumption. Furthermore, the C3 activation is observed and increased corresponding to the graded concentration of anti-OVA pAb[2]. |
分子量 | 526.51 |
分子式 | C24H29F3N4O6 |
CAS No. | 1140525-25-2 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 125 mg/mL (237.41 mM), sonification is recommended.
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 1.8993 mL | 9.4965 mL | 18.993 mL | 47.4825 mL |
5 mM | 0.3799 mL | 1.8993 mL | 3.7986 mL | 9.4965 mL | |
10 mM | 0.1899 mL | 0.9496 mL | 1.8993 mL | 4.7482 mL | |
20 mM | 0.095 mL | 0.4748 mL | 0.9496 mL | 2.3741 mL | |
50 mM | 0.038 mL | 0.1899 mL | 0.3799 mL | 0.9496 mL | |
100 mM | 0.019 mL | 0.095 mL | 0.1899 mL | 0.4748 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
SB290157 trifluoroacetate 1140525-25-2 Immunology/Inflammation Complement System SB290157 Trifluoroacetate SB290157 SB-290157 trifluoroacetate Inhibitor SB 290157 Trifluoroacetate inhibit SB 290157 SB-290157 SB-290157 Trifluoroacetate inhibitor